Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6472886 | 0.93 | L3MBTL1 (0.59) | L3MBTL1ALDH1A1SMN1; SMN2HTTMAPT | |
| SCHEMBL29173176 | 0.88 | L3MBTL1 (0.60) | L3MBTL1ALDH1A1SMN1; SMN2HTTMAPT | |
| SCHEMBL7239484 | 0.87 | L3MBTL1 (0.62) | L3MBTL1ALDH1A1SMN1; SMN2HTTMAPT | |
| SCHEMBL1313733 | 0.86 | L3MBTL1 (0.74) | L3MBTL1ALDH1A1SMN1; SMN2HTTMAPT | |
| SCHEMBL311599 | 0.85 | L3MBTL1 (0.59) | L3MBTL1ALDH1A1SMN1; SMN2HTTMAPT | |
| SCHEMBL6043383 | 0.82 | KDM4E (0.49) | L3MBTL1ALDH1A1SMN1; SMN2HTTMAPT | |
| SCHEMBL27466011 | 0.81 | RAB9A (0.51) | L3MBTL1ALDH1A1SMN1; SMN2HTTMAPT | |
| SCHEMBL6583837 | 0.81 | L3MBTL1 (0.55) | L3MBTL1ALDH1A1SMN1; SMN2HTTMAPT | |
| SCHEMBL6042513 | 0.79 | TSHR (0.59) | L3MBTL1ALDH1A1SMN1; SMN2HTTMAPT | |
| SCHEMBL27424667 | 0.79 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1SMN1; SMN2HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | ELAN PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| WO-2003103652-A1 | METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-5641778-A | EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0716077-A1 | Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors | CIBA-GEIGY AG (CH) | 1996-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | APP, BACE1, BACE2 | L3MBTL1 637/4885ALDH1A1 1039/4885SMN1; SMN2 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.